Systemic Lupus Erythematosus Market To Reach $4.26 Billion By 2030

Systemic Lupus Erythematosus Market Growth & Trends

The global systemic lupus erythematosus market size is expected to reach USD 4.26 billion by 2030, exhibiting a CAGR of 7.3% from 2024 to 2030, according to a new report by Grand View Research, Inc. Introduction of new biological therapies, which will add to treatment alternatives and medication costs, in the development pipeline is estimated to fuel revenue generation of the market. Certain new promising drugs that are currently in Phase III trials are anticipated to augment the market as these drugs may target the lupus nephritis patient subset with few effective alternatives and significant unmet needs to be met. This factor is likely to have a strong impact on the market as nearly 50.0% of SLE patients suffer with lupus nephritis.

Use of approved biologic, Benlysta, through clinical studies, has revealed drastic improvements and substantial decrease in consumption of anti-inflammatory glucocorticoids in moderate SLE cases. GSK’s current initiatives center on further increasing opportunities for Benlysta. The company is conducting indication expansion clinical trials, combination therapy studies with rituximab, and new product development, to widen opportunities for its therapy. In this direction, recent launch of Benlysta’s subcutaneous formulation in several countries is expected to boost the SLE market over the forecast period.

 Request a free sample copy or view report summary: Systemic Lupus Erythematosus Market Report

Systemic Lupus Erythematosus Market Report Highlights

• Immunosuppressants held the largest share in the market in 2023 due to their low cost and high accessibility, whereas the biologics segment is projected to post the highest CAGR during the same period

• The hospital pharmacy segment dominated the market in 2023. The growth of this segment is attributed to its widespread presence and specialized care offerings.

• The oral route of administration segment accounted for the largest revenue share in 2023. Growth of this segment is attributed to its convenience, ease of administration, and high patient compliance.

• North America dominated the global systemic lupus erythematosus market and accounted for the largest share of 39.4% in 2023. The region's dominance is attributed to the high prevalence of systemic lupus erythematosus, robust healthcare infrastructure, and awareness about autoimmune disease.

• Asia Pacific systemic lupus erythematosus market is anticipated to witness the fastest CAGR of 8.0% in 2023. Increasing SLE disease, awareness, and healthcare expenditure are the key factors expected to drive the region’s growth.

Systemic Lupus Erythematosus Market Segmentation

Grand View Research has segmented the global systemic lupus erythematosus market report based on drug class, route of administration, distribution channel, and region:

SLE Drug Class Outlook (Revenue, USD Million, 2018 - 2030)

• Biologics

  • Saphnelo (Anifrolumab)

  • Benlysta (Belimumab)

  • Phase 3 Pipeline Products

• TNF Inhibitors

• NSAID’s

• Corticosteroids

• Antimalarials

• Immunosuppressants

• Other Drug Classes

SLE Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

• Oral

• Intravenous

• Subcutaneous

• Other Route of Administration

SLE Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital Pharmacy

• Retail Pharmacy

• Online Pharmacy

SLE Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in Systemic Lupus Erythematosus (SLE) Market

• Novartis AG

• GSK plc.

• F. Hoffmann-La Roche Ltd

• Pfizer Inc.

• Sanofi

• Lycera (Celgene)

• Bristol-Myers Squibb Company

• ImmuPharma PLC

• Merck KgaA

• AstraZeneca

• UCB S.A.